Blood withdrawal: venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself
Study summary
This research aims to elucidate an underlying mechanism of maternal obesity induced pregnancy and longterm health complications for mothers and their offspring.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Participation in Predict study
* Preconceptional women who wish to become pregnant or pregnancy \<13 weeks of gestational age.
* BMI \> 30 kg/m2 or 18-25 kg/m2
* Understanding of Dutch in speaking and reading
* Willingness to give written informed consent
Exclusion Criteria:
* Age \< 18 years and \> 45 years.
* ≥13 weeks of gestational age
* Multiple pregnancy
* Smoking
* Gastro-intestinal diseases, heart diseases, liver, pancreas and kidney diseases.
* Use of antibiotics \< 2 weeks before sampling
* Pre-existent diabetes mellitus
Primary outcome measure(s)
Gut and vaginal microbiota — Preconceptional (up to 1 year before pregnancy) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16S ribosomal ribonucleic acid (16SrRNA) gene amplification sequencing (V6-V8). Sequences will be assigned to operational taxonomic units (OTUs).
Gut and vaginal microbiota — First trimester (between 7-12 weeks gestational age) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.
Gut and vaginal microbiota — Second trimester (between 22-25 weeks gestational age) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.
Gut and vaginal microbiota — Third trimester (between 30-32 weeks gestational age) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.
Gut and vaginal microbiota — Antepartum (during delivery) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.
Gut and vaginal microbiota — Postpartum (6-8 weeks post delivery) Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.
Trial sites (1)
Facility
City
Region
Status
Erasmus MC
Rotterdam
South Holland
Recruiting
More Erasmus Medical Center trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.